{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DOR is the time from date of first documentation of response to date of first documented PD. PD is increase of \\>=25% from lowest response value in any of following:Serum M-protein(increase must be \\>=0.5 gram per deciliter\\[g/dL\\];serum M component increases \\>=1 g/dL are sufficient to define relapse if starting M component is \\>=5 g/dL),and/or urine M-protein(increase must be \\>=200 mg/24 hour), and/or only in participants without measurable serum and urine M-protein levels, difference between involved/uninvolved FLC levels (increase must be \\>10 mg/dL), and only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage (percentage must be \\>=10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.","groups":[{"description":"Mezagitamab, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase was to be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study. However, Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.","id":"OG000","title":"Phase 2a: Mezagitamab"}],"populationDescription":"Data was not collected as Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3.7 years","title":"Phase 2a: Duration of Response (DOR)","type":"SECONDARY"}